Kelly Dewyer
Nurse Practitioner · Washington, DCNPI 1932579893
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 27 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 18.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $304, 9.4 times the $32 reported in 2021.
Across 27 payments — averaging $24.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$121
- Johnson & Johnson$114
- Merck$87
- AbbVie$32
- Coherus Oncology, Inc.$30
- Beone Medicines USA, Inc.$26
- plus $242 from 12 others
What the payments were for
- Food & beverage$651100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 5 | $121 |
| Johnson & Johnson | 4 | $114 |
| Merck | 3 | $87 |
| AbbVie | 1 | $32 |
| Coherus Oncology, Inc. | 1 | $30 |
| Beone Medicines USA, Inc. | 1 | $26 |
| Genentech USA, Inc. | 1 | $25 |
| AstraZeneca | 1 | $24 |
| E.r. Squibb & Sons, L.L.C. | 1 | $24 |
| GSK | 1 | $22 |
| Myriad Genetic Laboratories, Inc. | 1 | $21 |
| Incyte Corporation | 1 | $20 |
| Genmab U.S., Inc. | 1 | $20 |
| Novartis | 1 | $19 |
| Array Biopharma Inc | 1 | $19 |
| Seagen Inc. | 1 | $18 |
| Amgen | 1 | $15 |
| Pfizer | 1 | $14 |
How this compares
$651 in reported general payments places this provider in the 80th percentile of 224 nurse practitioner providers in District of Columbia.
See all nurse practitioner providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 14 | $196,379 |
| Imatinib Mesylate | 19 | $49,103 |
| Oxycodone Hcl | 36 | $482 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 12 | $361 |
| Prochlorperazine Maleate | 12 | $300 |
| Potassium Chloride | 12 | $264 |
| Gabapentin | 13 | $225 |
| Pantoprazole Sodium | 11 | $195 |
| Levothyroxine Sodium | 12 | $135 |
| Lactulose | 11 | $126 |
| Ondansetron Hcl | 17 | $123 |
| Tramadol Hcl | 11 | $29 |
Paid to pharmacies, not to this prescriber.
Other nurse practitioner in Washington
- Rasheda PersingerWashington$88K
- Caitlin YazelWashington$45K
- Aimee LestrangeWashington$37K
- Guinevere QueWashington$27K
- Cynthia BitherWashington$17K
- Safia AbdillahiWashington$11K
- Brigid ReynoldsWashington$6K
- Odette NtamWashington$5K
- Kathryn HilgartnerWashington$5K
- Mary AlderWashington$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.